Engineered Antigen-Presenting Cells for High-Throughput TCR Analysis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current technologies face challenges in efficiently and reliably analyzing and characterizing T-cell receptor (TCR) diversity and antigen interactions, particularly for therapeutic and diagnostic applications, due to the complex and highly individualized nature of TCR-antigen interactions, which are hindered by the lack of standardized, high-throughput systems for functional analysis in a cellular context.
Innovation Solution
A multi-component system comprising an engineered antigen-presenting cell (eAPC), a genetic donor vector, and genomic receiver sites is developed to rapidly generate stable derivative cells that present various antigenic molecules, enabling high-throughput identification and characterization of TCR sequences and antigens.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If conventional methods are used to analyze TCR-antigen interactions, then the analysis can be performed, but the process is time-consuming and low-throughput
Solution Approach 1:
The system segments the antigen presentation function across multiple independent eAPC components, each capable of presenting specific antigens. This modular approach enables parallel processing of multiple TCR-antigen interactions simultaneously, dramatically increasing throughput while reducing the time required for comprehensive functional analysis.
Solution Approach 2:
The patent employs engineered antigen-presenting cells (eAPCs) that can be rapidly generated and replicated to create large pools of standardized presentation cells. This copying approach allows parallel testing of multiple TCRs against multiple antigens simultaneously, achieving high-throughput analysis that would be impossible with conventional single-cell methods.
2Productivity
If high-throughput analysis is implemented, then productivity increases, but system complexity increases
Solution Approach 1:
The eAPC system is designed as a universal platform that can present multiple different antigens through standardized genomic receiver sites. This multi-functionality allows the same cell type to analyze different TCR-antigen interactions without requiring separate specialized systems for each antigen, thereby managing complexity while achieving high throughput.
Solution Approach 2:
The patent introduces engineered genomic receiver sites as intermediary elements that facilitate the integration and expression of antigen-encoding sequences in eAPCs. These standardized receiver sites act as mediators between the genetic information and the functional output, simplifying the overall system architecture while enabling high-throughput antigen presentation and analysis.
3Ease of operation
If standardized systems are developed, then ease of operation improves, but adaptability to different antigens may be limited
Solution Approach 1:
The system employs dynamic reconfigurability through recombinase-mediated cassette exchange (RMCE), allowing the same eAPC platform to be rapidly reconfigured to present different antigens by exchanging genetic cassettes at standardized receiver sites. This dynamic adaptability maintains ease of operation through standardization while enabling versatile analysis of different antigen types without requiring system redesign.
Solution Approach 2:
The patent utilizes parameter changes in the form of interchangeable genetic cassettes that can be exchanged at standardized genomic receiver sites. By changing the genetic parameters (antigen sequences) while maintaining the same structural framework (receiver sites and eAPC platform), the system achieves both standardization for ease of operation and adaptability for analyzing diverse antigen types.
Data Source
AI summary
The present invention relates to A multicomponent system wherein a first component is an engineered antigen-presenting cell (eAPC) designated component A and a second component is a genetic donor vector, designated component C, for delivery of one or more ORFs encoding an analyte antigen-presenting complex (aAPX) and/or an analyte antigenic molecule (aAM), wherein component A: Lacks endogenous surface expression of at least one family of aAPX and/or aAM and; Contains at least two genomic receiver sites, designated component B and component D, each for integration of at least one ORF encoding at least one aAPX and/or aAM; and component C is matched to a component B, and wherein component C is de-signed to deliver; A single ORF encoding at least one aAPX and/or aAM or; Two or more ORF encoding at least one aAPX and/or aAM; wherein the genomic receiver sites Band Dare synthetic constructs designed for recombinase mediated exchange (RMCE).